Deutsch English
» Main page » Products » Lipiscor® Capsules Login / Register  
 
 
 
Lipiscor® Capsules

 
 
Lipiscor® Capsules

 



Administration form:  Capsules
for oral intake
Preparation group:  Natural fatty acids
Active ingredient:  Piscis oleum (polyunsaturated fatty acids from sea fish)
Composition:  1 Capsule contains: Medically active substance: 500 mg Piscis oleum (polyunsaturated fatty acids from sea fish) containing 70 mg icosapent and 50 mg doconexent. Other constituents: RRR-α-tocopherol, al-rac-α-tocopherolum acetate, gelatin, glycerol, purified water.
Indication:  To lower a highly increased triglyceride blood level. Lipiscor® should only be administered additionally if a diet is insufficient in lowering triglyceride.
Characteristics:  Lipiscor® contains natural fish oil with a high content of essential polyunsaturated omega-3-(n-3) fatty acids, which are icosapent (eicosapentaenoic acid) and doconexent (docosahexaenoic acid). The results of epidemiological studies on populations such as Innuits, Japanese, Dutch and Americans show a correlation between a high intake of sea fish and a low appearance of cardiovascular diseases. The regular intake of Lipiscor® leads to a lowering of plasma triglycerides within four weeks. If taken on a permanent basis the triglyceride level will remain constant. If discontinued, the plasma triglycerides will return to their former level within 2-3 months. The omega-3 fatty acids contained in Lipiscor® go into the normal lipid metabolism, particularly the metabolism of eicosanoids and prostaglandins. The lipid-lowering effect of Lipiscor® is probably the result of an inhibition of the triglyceride synthesis. Taking Lipiscor® increases the proportion of omega-3-(n-3) fatty acids.
Application:  Unless otherwise prescribed: 5-10 capsules twice daily. Lipiscor® is to be swallowed unchewed with some liquid before a meal.
Side effects:  High dosages may occasionally cause nausea and eructation. Lipiscor® may prolong bleeding time and inhibit platelet aggregation. A modest increase in transaminases is possible.
Contraindications:  Acute and subacute pancreatitis, acute pancreas necrosis, acute and chronic liver intoxications, cirrhosis of the liver from all origins, acute to chronic cholecystitis, suppuration of the gall bladder, disorders of digestion as well as emulsification of fat in the small intestine due to diseases of the gallbladder and/or pancreas, thrombopathia, if allergic reactions against any of the ingredients are known.
Because Lipiscor® may cause a delay of uterine contractions it should not be administered in the last 3 months of pregnancy.
Interactions with other remedies:  Since Lipiscor® prolongs bleeding time and may reduce the platelet aggregation, patients with thrombopenia and patients who are treated with anticoagulant drugs should be under constant medical supervision as it might be necessary to reduce the administration of anticoagulant drugs.
Precautions:  As with all medications and due to the variations of clinical studies, professional medical advice should be sought prior to recommending this product to women during pregnancy or breastfeeding, as well as with children or in case of hypercholesterinaemia.
Advice:  None.
Warnings: 
Duration of treatment:  Dependent on the advice of the physician or health care professional.
Special precautions for storage: 
How supplied:  The following dosage forms are available: 60 and 240 capsules.